SREBF2 and metabolic dysfunction-associated steatotic liver disease: discovered that mTORC1/SREBP2 conducted abnormal cholesterol metabolism impairs antitumor immunosurveillance by causing NK cell dysfunction in hepatocellular carcinoma that develops from non-alcoholic fatty liver disease, inhibition of the mTORC1/SREBP2 may alleviate NK cell suppression to prevent obesity-promoted hepatocellular carcinoma (60, 61).